Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Exp Gerontol ; 145: 111219, 2021 03.
Article in English | MEDLINE | ID: mdl-33373712

ABSTRACT

Selenium (Se) is an essential micronutrient for human health that protects from oxidative damage. Se deficiency has been associated with the development of cardiovascular diseases (CVD). In this study we aimed to investigate the association between Se status, CVD risk, cardio-metabolic and inflammatory markers in elderly population. Se Plasma levels and inflammatory markers [neutrophil/lymphocyte ratio, serum C-reactive protein (CRP) levels and Copper/Zinc ratio (Cu/Zn)] were measured in 858 control subjects (mean age 73.4 ± 9.3) and 606 CVD patients (mean age 72.5± 8.7). A multivariate logistic regression was performed to evaluate the association between Se deficiency (Se< 60 µg/L) and the risk of CDV. In a subgroup of 46 CVD patients the gene expression of IL-1ß, CCL5/RANTES, IL-6, IL-8, IL-10, platelet-derived growth factor-ß (PDGFß) and sirtuins in peripheral blood mononuclear cell (PBMC) were further examined. Increased values of neutrophil/lymphocyte ratio, CRP levels and Cu/Zn ratio were observed in Se deficiency condition both in controls and in CVD patients. Moreover, enhanced gene expression of cytokines and chemokines such as IL1ß, CCL5 and PDGF- ß, and a downregulation of SIRT-1, SIRT-5, SIRT-6, SIRT-7 were found in PBMCs from CVD patients with Se deficiency. A multivariate logistic regression showed that Se deficiency was associated with an increased CVD risk (odds ratio=1.946, 95% CI: 1.19-3.18, p < 0.01). The current study revealed that Se deficiency is independently associated with CVD, and with elevated circulating inflammatory markers and affects the expression of cytokines, chemokines and sirtuins in PBMCs.


Subject(s)
Cardiovascular Diseases , Selenium , Aged , Aged, 80 and over , Humans , Inflammation , Italy/epidemiology , Leukocytes, Mononuclear
2.
EJVES Vasc Forum ; 47: 60-62, 2020.
Article in English | MEDLINE | ID: mdl-33078156

ABSTRACT

BACKGROUND: Strain gauge plethysmography (SGP) is employed to evaluate venous drainage of the lower leg. METHODS: In this study, SGP was used to evaluate the effects of the hydrostatic pressure (HP) of water on venous volume (VV), expelled volume, and ejection fraction (EF) in 22 healthy legs before and during immersion in water. RESULTS: HP reduced VV by 100% and even more during underwater (UW) exercise, making calculation of the UW EF possible. DISCUSSION: UW SGP is feasible and indicates that HP improves venous haemodynamics. This study suggests that including UW leg exercise in the rehabilitation protocols of patients with chronic venous disease may be useful. KEYWORDS: Strain gauge plethysmography, Underwater compression, Underwater ejection fraction, Underwater venous volume.

3.
Surg Open Sci ; 2(4): 5-11, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32885157

ABSTRACT

BACKGROUND: Limited studies have applied thoracic continuous spinal anesthesia in abdominal surgery, relying exclusively on opioids. This retrospective study analyzes 2 different schemes of thoracic continuous spinal anesthesia and postoperative analgesia in elderly patients undergoing major abdominal surgery. METHODS: A total of 98 patients aged ≥ 75 years were divided into 2 groups. The control group (60 patients) received bupivacaine plus fentanyl, whereas the study group (38 patients) received bupivacaine plus ketamine and midazolam. Both received analogous postoperative continuous intrathecal analgesia. Several perioperative variables were evaluated. RESULTS: Spinal anesthesia was performed without complications in all patients. Doses of noradrenaline administered, incidence of respiratory depression, need for intraoperative sedation, and time to first flatus were significantly reduced in the bupivacaine plus ketamine and midazolam group. CONCLUSION: In a population of frail, elderly patients, thoracic continuous spinal anesthesia with local anesthetic plus midazolam and ketamine was superior to local anesthetic plus fentanyl. In the group receiving local anesthetic plus midazolam and ketamine, the incidence of respiratory depression was reduced, and doses of norepinephrine and intraoperative sedating medications were lower. Intraoperative anesthesia and postoperative analgesia were similar in both groups.

4.
Int J Surg Case Rep ; 24: 104-7, 2016.
Article in English | MEDLINE | ID: mdl-27235589

ABSTRACT

INTRODUCTION: Giant colonic diverticulum (GCD), a rare complication of the diverticular disease, can present with a wide range of nonspecific symptoms as abdominal pain and bowel obstruction. Its diagnosis represents a challenge that mainly depends on imaging findings. PRESENTATION OF CASE: We report the case of a 79 year-old female patient that came to our emergency department complaining of 5-day history of hypogastric pain and constipation. Physical examination reveled a 15cm hypogastric round, tender and tympanic mass. Enhanced abdominal CT scan showed a large air-filled cyst adjacent to a diverticular sigmoid colon without evidence of intra-abdominal free air or fluid. Based on the radiological features, GCD was suspected and surgical treatment performed. The mass and the sigmoid colon were resected. The postoperative course was uneventful. Histopathology confirmed the preoperative diagnosis. DISCUSSION: GCD, defined as a diverticulum larger than 4cm, represents a rare complication of the diverticular disease. Usually abdominal X-ray and computed tomography (CT) scan show a gas-filled structure, sometimes communicating with the adjacent colon. GCD resection and segmental colectomy are strongly recommended even in asymptomatic cases due to the high incidence and severity of complications. CONCLUSION: Because of its rarity and variable and non-specific clinical presentation, the diagnosis of GCD depends mainly on imaging findings. The gold standard treatment is surgical resection of the GCD and the compromised colon with primary anastomosis when possible.

5.
J Antimicrob Chemother ; 62(6): 1332-8, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18799470

ABSTRACT

INTRODUCTION: An experimental study has been performed to compare the in vitro activity and the in vivo efficacy of magainin II and cecropin A with or without rifampicin against control and multidrug-resistant Pseudomonas aeruginosa strains. METHODS: In vitro experiments included MIC determinations and synergy studies. For in vivo studies, animals were given an intraperitoneal injection of P. aeruginosa lipopolysaccharide, P. aeruginosa ATCC 27853 and one clinical multiresistant P. aeruginosa strain. Groups of animals received intravenously isotonic sodium chloride solution, 10 mg/kg rifampicin, 1 mg/kg magainin II or 1 mg/kg cecropin A. Two groups of animals received a combined treatment with magainin II + rifampicin or cecropin A + rifampicin at the same dosages as the singly treated groups. In addition, a further group was treated with tazobactam/piperacillin (120 mg/kg). Lethality, bacterial growth in blood and peritoneum, and endotoxin and TNF-alpha concentrations in plasma were evaluated. RESULTS: Combinations of alpha-helical antimicrobial peptides showed in vitro synergistic interaction. Magainin II and cecropin A exerted strong antimicrobial activity and achieved a significant reduction in plasma endotoxin and TNF-alpha concentrations when compared with control and rifampicin-treated groups. Rifampicin exhibited no anti-P. aeruginosa activity and good substantial impact on endotoxin and TNF-alpha plasma concentrations. Combined treatment groups had significant reductions in bacterial count, positive blood cultures and mortality rates when compared with singly treated and control groups. CONCLUSIONS: Our results highlight the potential usefulness of these combinations that provide future therapeutic alternatives in P. aeruginosa infections.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Antimicrobial Cationic Peptides/therapeutic use , Pseudomonas Infections/drug therapy , Pseudomonas aeruginosa/drug effects , Rifampin/therapeutic use , Xenopus Proteins/therapeutic use , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacology , Antimicrobial Cationic Peptides/administration & dosage , Antimicrobial Cationic Peptides/pharmacology , Blood/microbiology , Drug Synergism , Drug Therapy, Combination , Endotoxins/blood , Injections, Intravenous , Magainins , Microbial Sensitivity Tests , Penicillanic Acid/analogs & derivatives , Penicillanic Acid/therapeutic use , Peritoneum/microbiology , Piperacillin/therapeutic use , Piperacillin, Tazobactam Drug Combination , Plasma/chemistry , Rats , Rats, Wistar , Rifampin/administration & dosage , Rifampin/pharmacology , Survival Analysis , Treatment Outcome , Tumor Necrosis Factor-alpha/blood , Xenopus Proteins/administration & dosage , Xenopus Proteins/pharmacology
6.
Crit Care Med ; 35(7): 1717-23, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17452938

ABSTRACT

OBJECTIVE: To investigate the efficacy of rifampin and colistin in three experimental rat models of Pseudomonas aeruginosa sepsis. DESIGN: Prospective, randomized, controlled animal study. SETTING: Research laboratory in a university hospital. SUBJECTS: Adult male Wistar rats. INTERVENTIONS: Adult male Wistar rats were given a) an intraperitoneal injection of 1 mg of P. aeruginosa 10 lipopolysaccharide; b) 2 x 10(10) colony-forming units of P. aeruginosa ATCC 27853; and c) 2 x 10(10) colony-forming units of one clinically multiresistant strain of P. aeruginosa. For each model, all animals were randomized to receive intravenously isotonic sodium chloride solution, 10 mg/kg rifampin, 1 mg/kg colistin, and 10 mg/kg rifampin plus 1 mg/kg colistin. MEASUREMENTS AND MAIN RESULTS: Lethality, bacterial growth in blood and peritoneum, and endotoxin and tumor necrosis factor-alpha concentrations in plasma were measured. Colistin exerted a strong antimicrobial activity and achieved a significant reduction of plasma endotoxin and tumor necrosis factor-alpha concentration compared with control and rifampin-treated groups. Rifampin exhibited no antimicrobial activity with no substantial impact on endotoxin and tumor necrosis factor-alpha plasma concentrations. The combination of colistin and rifampin resulted in a significant reduction in bacterial count compared with colistin monotherapy, whereas no significant difference was found in positive hem cultures and mortality rates between the two groups. CONCLUSIONS: Colistin and rifampin might have a role in the therapy of multiresistant P. aeruginosa infection.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Colistin/administration & dosage , Drug Resistance, Multiple, Bacterial , Pseudomonas Infections/drug therapy , Rifampin/administration & dosage , Shock, Septic/drug therapy , Animals , Anti-Bacterial Agents/pharmacology , Cells, Cultured , Colistin/pharmacology , Colony Count, Microbial , Drug Synergism , Drug Therapy, Combination , Male , Microbial Sensitivity Tests , Prospective Studies , Random Allocation , Rats , Rats, Wistar , Rifampin/pharmacology , Survival Analysis
7.
Peptides ; 27(11): 2600-6, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16797106

ABSTRACT

An experimental study has been performed to compare the in vitro activity and the in vivo efficacy of magainin II and cecropin A, two alpha-helical antimicrobial peptides, and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides. In vitro experiments included MIC determination, time-kill and synergy studies. For in vivo studies, a mouse model of staphylococcal sepsis has been used. Main outcome measures were: lethality, quantitative blood cultures and detection of TNF-alpha and interleukin-6 (IL-6) plasma levels. Combinations of alpha-helical antimicrobial peptides showed in vitro synergistic interaction. Significant increase in efficacy was also observed in vivo: combined-treated groups had significant lower bacteremia when compared to single-treated groups. Magainin II combined with vancomycin exhibited the highest efficacy on all main outcome measurements. These results highlight the potential usefulness of these combinations and provide future therapeutic alternative in infections due to glycopeptides resistant staphylococci in the coming years.


Subject(s)
Antimicrobial Cationic Peptides/pharmacology , Drug Resistance, Bacterial , Glycopeptides/pharmacology , Staphylococcal Infections/drug therapy , Staphylococcus aureus/drug effects , Vancomycin/pharmacology , Animals , Disease Models, Animal , Drug Resistance, Multiple, Bacterial , Drug Therapy, Combination , Male , Mice , Mice, Inbred BALB C , Microbial Sensitivity Tests , Protein Structure, Secondary
8.
Peptides ; 27(6): 1210-6, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16289474

ABSTRACT

An in vitro antibiotic susceptibility assay for Staphylococcus aureus biofilms developed on 96-well polystyrene tissue culture plates was performed to elucidate the activity of citropin 1.1, rifampin and minocycline. Efficacy studies were performed in a rat model of staphylococcal CVC infection. Silastic catheters were implanted into the superior cava. Twenty-four hours after implantation the catheters were filled with citropin 1.1 (10 microg/mL). Thirty minutes later the rats were challenged via the CVC with 1.0 x 10(6) CFU of S. aureus strain Smith diffuse. Administration of antibiotics into the CVC (the antibiotic lock technique) began 24 h later. The study included: one control group (no CVC infection), one contaminated group that did not receive any antibiotic prophylaxis, one contaminated group that received citropin 1.1-treated CVC, two contaminated groups that received citropin 1.1-treated CVC plus rifampin and minocycline at concentrations equal to MBCs for adherent cells and 1024 microg/mL in a volume of 0.1 mL that filled the CVC and two contaminated groups that received rifampin or minocycline at the same concentrations. All catheters were explanted 7 days after implantation. Main outcome measures were: minimal inhibitory concentration (MIC), minimal bactericidal concentration (MBC), synergy studies, quantitative culture of the biofilm formed on the catheters and surrounding venous tissues, and quantitative peripheral blood cultures. MICs of conventional antibiotics against the bacteria in a biofilm were at least four-fold higher than against the freely growing planktonic cells. In contrast, when antibiotics were used on citropin 1.1 pre-treated cells they showed comparable activity against both biofilm and planktonic organisms. The in vivo studies show that when CVCs were pre-treated with citropin 1.1 or with a high dose of antibiotics, biofilm bacterial load was reduced from 10(7) to 10(3) CFU/mL and bacteremia reduced from 10(3) to 10(1) CFU/mL. When CVCs were treated both with citropin 1.1 and antibiotics, biofilm bacterial load was further reduced to 10(1) CFU/mL and bacteremia was not detected, suggesting 100% elimination of bacteremia and a log 6 reduction in biofilm load. Citropin 1.1 significantly reduces bacterial load and enhances the effect of hydrophobic antibiotics in the treatment of CVC-associated S. aureus infections.


Subject(s)
Amphibian Proteins/metabolism , Anti-Infective Agents/pharmacology , Antimicrobial Cationic Peptides/metabolism , Staphylococcal Infections/drug therapy , Animals , Biofilms , Catheterization/adverse effects , Catheterization, Central Venous/adverse effects , Male , Microbial Sensitivity Tests , Minocycline/pharmacology , Polystyrenes/chemistry , Rats , Rats, Wistar , Rifampin/pharmacology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...